3-((2S,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tarahydrofuran-2-yl)acrylonitrile

ID: ALA4875489

PubChem CID: 164627940

Max Phase: Preclinical

Molecular Formula: C14H15N5O4

Molecular Weight: 317.31

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  N#C/C=C/[C@@]1(c2ccc3c(N)ncnn23)O[C@H](CO)[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C14H15N5O4/c15-5-1-4-14(12(22)11(21)9(6-20)23-14)10-3-2-8-13(16)17-7-18-19(8)10/h1-4,7,9,11-12,20-22H,6H2,(H2,16,17,18)/b4-1+/t9-,11-,12-,14+/m1/s1

Standard InChI Key:  HZWJIAAZXKHPSO-VUOVTKDLSA-N

Molfile:  

 
     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
   24.8739   -4.2748    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.5859   -3.8666    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.5859   -3.0416    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.8739   -2.6250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.1619   -3.8666    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.1619   -3.0416    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3773   -2.7866    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.8924   -3.4540    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3772   -4.1214    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1252   -4.9072    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.3406   -5.1622    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   22.3406   -5.9872    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1253   -6.2421    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6100   -5.5747    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.6732   -6.4721    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3802   -7.0267    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.3933   -5.9497    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   23.9869   -5.0749    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.9194   -6.1365    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.8739   -1.8000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.7014   -4.6624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.4158   -5.0749    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.1447   -5.4958    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  6  4  1  0
  5  1  1  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  5  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 10  1  0
 10  9  1  1
 12 15  1  1
 13 16  1  6
 14 17  1  6
 10 18  1  0
 15 19  1  0
  4 20  1  0
 18 21  2  0
 21 22  1  0
 22 23  3  0
M  END

Alternative Forms

1. Parent:

   

   ALA4875489

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 317.31

Molecular Weight (Monoisotopic): 317.1124

AlogP: -1.30

#Rotatable Bonds: 3

Polar Surface Area: 149.92

Molecular Species: NEUTRAL

HBA: 9

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 5

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.57

CX Basic pKa: 0.73

CX LogP: -1.34

CX LogD: -1.34

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.51

Np Likeness Score: 0.52

References

1. Wei D, Hu T, Zhang Y, Zheng W, Xue H, Shen J, Xie Y, Aisa HA..  (2021)  Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2.,  46  [PMID:34450570] [10.1016/j.bmc.2021.116364]

Source

Source(1):

• Scientific Literature